Ascendis Pharma A/S (ASND)
| Previous close | 136.93 |
| Open | 137.00 |
| Bid | 135.82 x 100 |
| Ask | 136.28 x 100 |
| Day's range | 133.39 - 139.80 |
| 52-week range | 66.03 - 161.00 |
| Volume | |
| Avg. volume | 352,493 |
| Market cap | 7.669B |
| Beta (5Y monthly) | 0.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.15 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.29 |
GlobeNewswireAscendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
COPENHAGEN, Denmark, April 25, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2024 financial results and provide a business update on Thursday, May 2, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on May 2, 2024, at 4:30 p.m. Eastern Time (ET) to discuss its first quarter 2024 financial results. Those who would like to participate may access the live webcast here, or
ZacksWhy Earnings Season Could Be Great for Ascendis Pharma (ASND)
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- GlobeNewswire
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
COPENHAGEN, Denmark, April 24, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United Kingdom’s Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for YORVIPATH® (palopegteriparatide; developed as TransCon™ PTH) in Great Britain as a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, and has also granted YORVIPATH orphan drug status. YORVIPATH is a prod
